We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+19.82%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.84B
AUM Growth
+$680M
Cap. Flow
+$205M
Cap. Flow %
7.2%
Top 10 Hldgs %
32.58%
Holding
110
New
34
Increased
20
Reduced
17
Closed
25

Top Buys

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$55M
2
LLY icon
Eli Lilly
LLY
+$52.4M
3
MCK icon
McKesson
MCK
+$51.5M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$41.6M
5
ABBV icon
AbbVie
ABBV
+$40.8M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$114M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$30.6M
3
XYZ
Block Inc
XYZ
+$29.5M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$20.8M
5
MSFT icon
Microsoft
MSFT
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 79.08%
2 Financials 0.38%
3 Consumer Discretionary 0%
4 Industrials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
26
CALL
Biogen
BIIB
$30.5B
$39.2M 1.38%
+160,000
New +$41.3M
DHR icon
27
Danaher
DHR
$140B
$38M 1.34%
193,172
+8,560
+5% +$1.72M
UNH icon
28
UnitedHealth
UNH
$375B
$35.8M 1.26%
+102,099
New +$34.2M
XLF icon
29
CALL
State Street Financial Select Sector SPDR ETF
XLF
$58.6B
$35M 1.23%
+1,188,100
New +$31.8M
PEN icon
30
Penumbra
PEN
$12.7B
$34.9M 1.23%
199,694
-39,703
-17% -$8.7M
BMRN icon
31
CALL
BioMarin Pharmaceuticals
BMRN
$11.6B
$32.6M 1.15%
371,700
+85,500
+30% +$6.78M
HUM icon
32
Humana
HUM
$43.7B
$31.9M 1.12%
77,740
– –
AERI
33
DELISTED
Aerie Pharmaceuticals
AERI
$30.1M 1.06%
2,227,611
– –
GH icon
34
Guardant Health
GH
$21.9B
$29.4M 1.03%
+227,876
New +$26.2M
MYOV
35
DELISTED
Myovant Sciences Ltd.
MYOV
$28.9M 1.02%
1,046,212
+417,940
+67% +$8.14M
BIIB icon
36
Biogen
BIIB
$30.5B
$28.1M 0.99%
114,604
+24,888
+28% +$6.42M
BMY icon
37
Bristol-Myers Squibb
BMY
$130B
$28M 0.98%
+451,275
New +$27.7M
BMRN icon
38
BioMarin Pharmaceuticals
BMRN
$11.6B
$27.6M 0.97%
314,499
-385,553
-55% -$30.6M
HSIC icon
39
Henry Schein
HSIC
$10.2B
$26.4M 0.93%
395,161
-7,149
-2% -$461K
LH icon
40
Labcorp
LH
$25.4B
$26.1M 0.92%
149,108
-17,720
-11% -$3.06M
PPD
41
DELISTED
PPD, Inc. Common Stock
PPD
$25.4M 0.89%
742,863
-45,000
-6% -$1.57M
PFE icon
42
Pfizer
PFE
$147B
$25.2M 0.89%
685,125
+180,933
+36% +$6.64M
NVAX icon
43
Novavax
NVAX
$1.27B
$24.1M 0.85%
+215,908
New +$22.9M
TCRR
44
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$24M 0.84%
775,794
– –
ICLR icon
45
Icon
ICLR
$12.6B
$23.7M 0.83%
121,323
– –
WAT icon
46
Waters Corp
WAT
$39.3B
$23.4M 0.82%
+94,497
New +$21.4M
IOVA icon
47
PUT
Iovance Biotherapeutics
IOVA
$1.94B
$23.2M 0.82%
+500,000
New +$19.9M
CANO
48
DELISTED
Cano Health, Inc.
CANO
$22.4M 0.79%
+16,696
New +$19.1M
MOH icon
49
Molina Healthcare
MOH
$10.2B
$21.7M 0.76%
101,907
-60,617
-37% -$12.5M
LUNG icon
50
Pulmonx
LUNG
$83.6M
$20.3M 0.71%
+302,631
New +$14.8M
1
2
3 4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

PFM Health Sciences's Q4 2020 Portfolio in Review

As of Q4 2020, PFM Health Sciences held 110 positions worth $2.84B, up 31% from $2.16B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

PFM Health Sciences deployed $205M of net new capital in Q4 2020, opening 34 new positions and adding to 20 existing holdings. Its largest new stake was Universal Health Services: 442,044 shares worth $60.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 68% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $30.6M trimmed.

  • PFM Health Sciences's largest Q4 2020 buy was Universal Health Services: 442,044 shares worth $60.8M.
  • PFM Health Sciences added most to Acadia Pharmaceuticals in Q4 2020, an estimated $41.6M increase.
  • PFM Health Sciences's biggest Q4 2020 reduction was BioMarin Pharmaceuticals, cutting an estimated $30.6M.
  • PFM Health Sciences fully exited Immunomedics Inc in Q4 2020, selling an estimated $114M.
  • PFM Health Sciences's ten largest holdings make up 33% of its $2.84B portfolio in Q4 2020.
  • PFM Health Sciences opened 34 new positions and closed 25 in Q4 2020.
  • PFM Health Sciences's portfolio value rose 31% quarter-over-quarter to $2.84B.

Based on PFM Health Sciences's 13F filing for Q4 2020, filed 16 Feb 2021.